MA56074B1 - Anticorps contre le sars-cov-2 - Google Patents

Anticorps contre le sars-cov-2

Info

Publication number
MA56074B1
MA56074B1 MA56074A MA56074A MA56074B1 MA 56074 B1 MA56074 B1 MA 56074B1 MA 56074 A MA56074 A MA 56074A MA 56074 A MA56074 A MA 56074A MA 56074 B1 MA56074 B1 MA 56074B1
Authority
MA
Morocco
Prior art keywords
cov
antibodies against
formula
compound represented
against sars
Prior art date
Application number
MA56074A
Other languages
English (en)
Other versions
MA56074A (fr
Inventor
Davide Corti
Florian A Lempp
Amalio Telenti
Katja Fink
Martina Beltramello
Elisabetta Cameroni
Dora Pinto
Gyorgy Snell
Original Assignee
Vir Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vir Biotechnology Inc filed Critical Vir Biotechnology Inc
Publication of MA56074A publication Critical patent/MA56074A/fr
Publication of MA56074B1 publication Critical patent/MA56074B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne l'utilisation d'un composé représenté par la formule (i) ou de ses sels pharmaceutiquement acceptables dans la préparation de médicaments pour prévenir ou traiter les maladies infectieuses à coronavirus. Le composé représenté par la formule (i) est utilisé pour traiter les patients atteints d'une pneumonie causée par un nouveau coronavirus, et présente des avantages évidents en ce qui concerne le rapport de conversion négative du test d'acide nucléique viral, le cours de conversion négative et le temps de guérison et de sortie de l'hôpital.
MA56074A 2020-02-26 2021-02-25 Anticorps contre le sars-cov-2 MA56074B1 (fr)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US202062981984P 2020-02-26 2020-02-26
US202062982661P 2020-02-27 2020-02-27
US202062987298P 2020-03-09 2020-03-09
US202062989522P 2020-03-13 2020-03-13
US202062990369P 2020-03-16 2020-03-16
US202062992082P 2020-03-19 2020-03-19
US202062994235P 2020-03-24 2020-03-24
US202063001204P 2020-03-27 2020-03-27
US202063003214P 2020-03-31 2020-03-31
US202063005206P 2020-04-03 2020-04-03
US202063010589P 2020-04-15 2020-04-15
US202063011971P 2020-04-17 2020-04-17
US202063014024P 2020-04-22 2020-04-22
US202063023788P 2020-05-12 2020-05-12
US202063025133P 2020-05-14 2020-05-14
US202063039813P 2020-06-16 2020-06-16
US202063043653P 2020-06-24 2020-06-24
US202063050331P 2020-07-10 2020-07-10
US202063052810P 2020-07-16 2020-07-16

Publications (2)

Publication Number Publication Date
MA56074A MA56074A (fr) 2022-04-06
MA56074B1 true MA56074B1 (fr) 2023-11-30

Family

ID=74758682

Family Applications (1)

Application Number Title Priority Date Filing Date
MA56074A MA56074B1 (fr) 2020-02-26 2021-02-25 Anticorps contre le sars-cov-2

Country Status (24)

Country Link
US (3) US11168128B2 (fr)
EP (2) EP4245373A3 (fr)
JP (2) JP7275405B2 (fr)
KR (1) KR20220164465A (fr)
AU (2) AU2021227687B2 (fr)
BR (1) BR112022017048A2 (fr)
CA (1) CA3158752C (fr)
CL (1) CL2022002335A1 (fr)
CO (1) CO2022013525A2 (fr)
DK (1) DK3872091T5 (fr)
ES (1) ES2954629T3 (fr)
FI (1) FI3872091T3 (fr)
HR (1) HRP20231031T1 (fr)
HU (1) HUE062777T2 (fr)
IL (1) IL295801A (fr)
LT (1) LT3872091T (fr)
MA (1) MA56074B1 (fr)
MX (1) MX2022010537A (fr)
PL (1) PL3872091T3 (fr)
PT (1) PT3872091T (fr)
RS (1) RS64645B1 (fr)
SG (1) SG11202110145SA (fr)
SI (1) SI3872091T1 (fr)
WO (1) WO2021173753A1 (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11680101B2 (en) 2017-01-27 2023-06-20 Kymab Limited Anti-OPG antibodies
MX2022011892A (es) * 2020-03-26 2022-10-18 Univ Vanderbilt Anticuerpos monoclonales humanos dirigidos contra el coronavirus 2 del sindrome respiratorio agudo grave (sars-cov-2).
SG11202103404PA (en) 2020-04-02 2021-04-29 Regeneron Pharma Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
US11192940B2 (en) 2020-04-10 2021-12-07 Adagio Therapeutics, Inc. Compounds specific to coronavirus S protein and uses thereof
WO2021247779A1 (fr) 2020-06-03 2021-12-09 Regeneron Pharmaceuticals, Inc. Méthodes de traitement ou de prévention d'infections au sars-cov-2 et de la covid-19 à l'aide d'anticorps de glycoprotéine de spicule anti-sars-cov-2
BR112022025229A2 (pt) * 2020-06-12 2023-03-07 Vir Biotechnology Inc Terapias de anticorpos para infecção por sars-cov-2
JP2023534923A (ja) * 2020-07-06 2023-08-15 フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー ＳＡＲＳ－ＣｏＶ－２を標的にする抗原結合分子
IL300720A (en) 2020-08-26 2023-04-01 Flagship Pioneering Innovations Vi Llc Antigen binding molecules targeting Sars-cov-2
WO2022054068A1 (fr) * 2020-09-14 2022-03-17 Ramot At Tel-Aviv University Ltd. Anticorps pour la prévention, le traitement et la détection d'une infection à coronavirus
WO2022066297A1 (fr) * 2020-09-22 2022-03-31 Becton, Dickinson And Company Dosage à base de cellules pour la détection d'anticorps dans un échantillon
EP4228697A1 (fr) 2020-10-16 2023-08-23 Invisishield Technologies Ltd. Compositions pour la prévention ou le traitement d'infections virales et d'autres infections microbiennes
US12109237B2 (en) * 2020-12-15 2024-10-08 Rutgers, The State University Of New Jersey S309 chimeric antigen receptors and methods of use
WO2023001736A1 (fr) 2021-07-19 2023-01-26 Universität Für Bodenkultur Wien Anticorps igg3 anti-sars-cov-2 modifiés
JP2024533166A (ja) * 2021-09-01 2024-09-12 ヴィア・バイオテクノロジー・インコーポレイテッド 小児被験体におけるＳＡＲＳ－ＣｏＶ－２感染の抗体療法
WO2023034871A1 (fr) * 2021-09-01 2023-03-09 Vir Biotechnology, Inc. Thérapies par anticorps à haute concentration contre infection par sars-cov-2
WO2023039442A1 (fr) * 2021-09-08 2023-03-16 Vir Biotechnology, Inc. Polythérapies à base d'anticorps à large spectre de neutralisation pour infection par sars-cov-2
WO2023039540A2 (fr) * 2021-09-10 2023-03-16 Jacobs Technion-Cornell Institute Compositions et procédés pour déterminer des réponses immunitaires humorales contre des coronavirus saisonniers et prédire l'efficacité de ciblage de spicule du sars-cov-2, gravité de maladie covid-19, et pour permettre des interventions
WO2023044397A1 (fr) * 2021-09-15 2023-03-23 The Board Of The Trustees Of The University Of Illinois Récepteurs modifiés et anticorps monoclonaux contre les coronavirus et leurs utilisations
WO2023046057A1 (fr) * 2021-09-24 2023-03-30 南京金斯瑞生物科技有限公司 Anticorps monoclonal dirigé contre le mutant l452r de protéine de spicule de sars-cov-2 et son utilisation
WO2023086827A1 (fr) * 2021-11-09 2023-05-19 Rhode Island Hospital Prédiction d'anticorps contre la covid-19 parmi des survivants avec séquençage d'arn profond
WO2023086635A1 (fr) 2021-11-15 2023-05-19 Vir Biotechnology, Inc. Substituts virologiques et moléculaires de réponse à l'anticorps neutralisant le sars-cov-2 sotrovimab
WO2023094980A1 (fr) * 2021-11-23 2023-06-01 Fondazione Toscana Life Sciences Anticorps contre le coronavirus
CN114107223B (zh) * 2021-11-25 2024-03-26 湖北省疾病预防控制中心（湖北省预防医学科学院） 利用TPCK胰酶提高SARS-CoV-2病毒细胞培养滴度的方法
WO2023122211A2 (fr) * 2021-12-21 2023-06-29 Duke University Anticorps du coronavirus et leurs utilisations
WO2023130123A2 (fr) * 2022-01-03 2023-07-06 Twist Bioscience Corporation Anticorps bispécifiques du sars-cov-2 et procédés d'utilisation
WO2023133509A2 (fr) * 2022-01-08 2023-07-13 Carogen Corporation Vaccins thérapeutiques à antigènes multiples pour traiter ou prévenir une infection chronique par le virus de l'hépatite b
CN116444656B (zh) * 2022-01-10 2023-09-22 东莞市朋志生物科技有限公司 一种鉴别新冠突变型抗原的抗体、试剂及方法
WO2023147251A1 (fr) * 2022-01-26 2023-08-03 Academia Sinica Anticorps spécifique de coronavirus et ses utilisations
WO2023150307A2 (fr) * 2022-02-03 2023-08-10 Abpro Corporation Compositions et méthodes contre un virus
TW202342510A (zh) 2022-02-18 2023-11-01 英商Ｒｑ生物科技有限公司 抗體
WO2023201256A1 (fr) * 2022-04-12 2023-10-19 Vir Biotechnology, Inc. Thérapies par anticorps à haute dose contre une infection par le sars-cov-2
WO2023215910A1 (fr) 2022-05-06 2023-11-09 Generate Biomedicines, Inc. Molécules de liaison à l'antigène ciblant le sars-cov-2
US20230365658A1 (en) * 2022-05-16 2023-11-16 Lawrence Livermore National Security, Llc REPAIRED THERAPEUTIC AND PROPHYLACTIC ANTIBODIES AGAINST SARS-CoV-2 VARIANTS
KR20240008997A (ko) * 2022-07-12 2024-01-22 (재) 스크립스코리아항체연구원 사스-코로나 바이러스 2 중화 항체
WO2024058987A2 (fr) * 2022-09-14 2024-03-21 Merck Sharp & Dohme Llc Polypeptides efficaces contre de multiples coronavirus
WO2024102674A1 (fr) 2022-11-13 2024-05-16 Generate Biomedicines, Inc. Molécules de liaison à l'antigène ciblant sars-cov-2
WO2024112818A1 (fr) * 2022-11-22 2024-05-30 Humabs Biomed Sa Anticorps anti-sars-cov-2 modifiés et leurs utilisations

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
NZ517906A (en) 1999-10-04 2003-01-31 Medicago Inc Cloning of genomic sequences encoding nitrite reductase (NiR) for use in regulated expression of foreign genes in host plants
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
AU2003272511A1 (en) 2002-09-13 2004-04-30 Dyax Corporation Cd44-binding ligands
AU2004215125B2 (en) 2003-02-26 2011-01-06 Institute For Research In Biomedicine Monoclonal antibody production by EBV transformation of B cells
TW200508247A (en) 2003-04-08 2005-03-01 Vironovative Bv Sars
KR101206206B1 (ko) 2003-07-22 2012-11-29 크루셀 홀란드 비.브이. 사스-코로나바이러스에 대한 결합분자 및 그것의 용도
EP1644414B1 (fr) 2003-07-22 2015-01-14 Crucell Holland B.V. Molecules de liaison dirigees contre le coronavirus du syndrome respiratoire aigu severe et applications de celles-ci
US7396914B2 (en) 2003-08-04 2008-07-08 University Of Massachusetts SARS nucleic acids, proteins, antibodies, and uses thereof
ATE492562T1 (de) 2003-09-24 2011-01-15 Kyowa Hakko Kirin Co Ltd Rekombinanter antikörper gegen humanen insulin- like growth factor
US7750123B2 (en) 2003-11-25 2010-07-06 Dana Farber Cancer Institute, Inc. Antibodies against SARS-CoV and methods of use thereof
US7553944B2 (en) 2004-07-21 2009-06-30 The University Of Hong Kong Human virus causing respiratory tract infection and uses thereof
SG159542A1 (en) 2004-11-11 2010-03-30 Crucell Holland Bv Compositions against sars-coronavirus and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2008060331A2 (fr) 2006-05-19 2008-05-22 Amgen Inc. Anticorps au coronavirus sras
PT2511301T (pt) 2006-08-04 2018-03-08 Medimmune Ltd Anticorpos humanos para erbb2
WO2008042814A2 (fr) 2006-09-29 2008-04-10 California Institute Of Technology Récepteurs mart-1 des lymphocytes t
BRPI0808673A2 (pt) 2007-03-06 2014-08-12 Symphogen As Anticorpos recombinantes para tratamento de infecções com vírus sinciciais respiratórios.
US20110159001A1 (en) 2008-01-17 2011-06-30 Institute For Research In Biomedicine CROSS-NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES TO SARS-CoV AND METHODS OF USE THEREOF
US20110004955A1 (en) 2008-01-30 2011-01-06 Monsanto Technology Llc Transgenic plants with enhanced agronomic traits
WO2010107752A2 (fr) 2009-03-20 2010-09-23 Amgen Inc. Anticorps antagoniste spécifique d'un hétérodimère alpha-4-bêta-7
WO2011056997A1 (fr) 2009-11-04 2011-05-12 Fabrus Llc Procédés pour l'optimisation d'anticorps basée sur la maturation d'affinité
MX359551B (es) 2009-11-24 2018-10-02 Medimmune Ltd Agentes de union diana contra b7-h1.
JO3274B1 (ar) 2009-12-24 2018-09-16 Regeneron Pharma أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري
KR101299753B1 (ko) 2010-11-19 2013-08-23 주식회사 단바이오텍 소 코로나바이러스 항원 결정기를 포함하는 스파이크 재조합 단백질 및 이에 대한 항체
HUE041900T2 (hu) 2012-01-20 2019-06-28 Genzyme Corp Anti-CXCR3 ellenanyagok
AR090244A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Formulacion de anticuerpo anti-selectina p
CN104379734B (zh) 2012-05-18 2018-05-15 诺维信公司 具有改进的转化效率的细菌突变体
TWI641619B (zh) 2012-06-25 2018-11-21 美商再生元醫藥公司 抗－ｅｇｆｒ抗體及其用途
EP4071177A1 (fr) 2013-12-30 2022-10-12 Epimab Biotherapeutics, Inc. Immunoglobuline fabs-in-tandem et ses utilisations
JO3701B1 (ar) 2014-05-23 2021-01-31 Regeneron Pharma مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
AR101669A1 (es) 2014-07-31 2017-01-04 Amgen Res (Munich) Gmbh Constructos de anticuerpos para cdh19 y cd3
WO2016073906A2 (fr) 2014-11-06 2016-05-12 Scholar Rock, Inc. Immunoessais liés à des facteurs de croissance transformants
TWI710573B (zh) 2015-01-26 2020-11-21 美商再生元醫藥公司 抗伊波拉病毒醣蛋白之人類抗體
KR20170140180A (ko) 2015-02-24 2017-12-20 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 중동 호흡기 증후군 코로나 바이러스 면역원, 항체 및 그 용도
IL283764B2 (en) 2015-04-10 2024-01-01 Amgen Inc Interleukin for the expansion of myotonic control T-2 cells
KR20170141256A (ko) 2015-05-08 2017-12-22 유레카 쎄라퓨틱스, 인코포레이티드 Hpv16-e7 펩티드/mhc 복합체를 표적화하는 구축물 및 그의 용도
US11267899B2 (en) 2015-05-13 2022-03-08 Zumutor Biologics Inc. Afucosylated protein, cell expressing said protein and associated methods
US10358497B2 (en) 2015-09-29 2019-07-23 Amgen Inc. Methods of treating cardiovascular disease with an ASGR inhibitor
JP7270379B2 (ja) 2016-03-08 2023-05-10 イナート・ファルマ・ソシエテ・アノニム Ｓｉｇｌｅｃ中和抗体
WO2017220990A1 (fr) 2016-06-20 2017-12-28 Kymab Limited Anticorps anti-pd-l1
US10759855B2 (en) 2016-12-02 2020-09-01 Rigel Pharmaceuticals, Inc. Antigen binding molecules to TIGIT
EP3555625A1 (fr) 2016-12-16 2019-10-23 Merck Patent GmbH Méthodes d'utilisation de la protéine de liaison à la galectine 3 détectée dans l'urine pour surveiller la gravité et la progression de la néphropathie lupique
US11680101B2 (en) 2017-01-27 2023-06-20 Kymab Limited Anti-OPG antibodies
CN110914295B (zh) 2017-06-28 2024-08-09 里珍纳龙药品有限公司 抗人乳头瘤病毒(hpv)抗原结合蛋白及其使用方法
WO2019024979A1 (fr) 2017-07-31 2019-02-07 Institute For Research In Biomedicine Anticorps à domaines fonctionnels dans la région de coude
WO2019028555A1 (fr) 2017-08-09 2019-02-14 University Of Saskatchewan Agents de liaison à her3 et utilisations associées
KR101895228B1 (ko) 2017-08-23 2018-10-30 대한민국 중동호흡기증후군 코로나바이러스의 스파이크 단백질에 대한 단일클론항체 및 이의 용도
IL310960A (en) 2017-09-22 2024-04-01 Wuxi Biologics Ireland Ltd New bispecific polypeptide complexes
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
SG11202103404PA (en) * 2020-04-02 2021-04-29 Regeneron Pharma Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
WO2021203053A1 (fr) * 2020-04-03 2021-10-07 Vir Biotechnology, Inc. Immunothérapie ciblant une région conservée dans des coronavirus sras
WO2021211775A1 (fr) * 2020-04-14 2021-10-21 Vir Biotechnology, Inc. Anticorps dirigés contre le sras-cov-2 et leurs procédés d'utilisation
MX2022013886A (es) * 2020-05-08 2022-11-30 Vir Biotechnology Inc Anticuerpos contra coronavirus de tipo 2 causante del sindrome respiratorio agudo severo (sars-cov-2).
WO2021247925A1 (fr) * 2020-06-03 2021-12-09 Vir Biotechnology, Inc. Immunothérapie guidée par une structure dirigée contre le sars-cov-2
BR112022025229A2 (pt) * 2020-06-12 2023-03-07 Vir Biotechnology Inc Terapias de anticorpos para infecção por sars-cov-2
CN112062859B (zh) * 2020-07-24 2022-08-09 沣潮医药科技（上海）有限公司 用于病原体清除的嵌合抗原受体及其应用

Also Published As

Publication number Publication date
WO2021173753A1 (fr) 2021-09-02
CL2022002335A1 (es) 2023-07-21
MA56074A (fr) 2022-04-06
MX2022010537A (es) 2022-09-21
EP3872091B1 (fr) 2023-06-14
AU2023203201A1 (en) 2023-06-15
CA3158752C (fr) 2023-08-08
CO2022013525A2 (es) 2022-12-20
JP2023009046A (ja) 2023-01-19
HUE062777T2 (hu) 2023-12-28
BR112022017048A2 (pt) 2022-11-16
RS64645B1 (sr) 2023-10-31
US11479599B2 (en) 2022-10-25
CA3158752A1 (fr) 2021-09-02
SG11202110145SA (en) 2021-10-28
US20210371504A1 (en) 2021-12-02
US20230331821A1 (en) 2023-10-19
IL295801A (en) 2022-10-01
TW202146442A (zh) 2021-12-16
US11168128B2 (en) 2021-11-09
PL3872091T3 (pl) 2023-12-27
FI3872091T3 (fi) 2023-08-31
EP4245373A3 (fr) 2023-12-20
AU2021227687A1 (en) 2022-10-20
LT3872091T (lt) 2023-10-10
DK3872091T5 (da) 2024-08-12
EP3872091A1 (fr) 2021-09-01
EP4245373A2 (fr) 2023-09-20
KR20220164465A (ko) 2022-12-13
HRP20231031T1 (hr) 2023-12-22
ES2954629T3 (es) 2023-11-23
DK3872091T3 (da) 2023-09-11
US20210261650A1 (en) 2021-08-26
PT3872091T (pt) 2023-09-19
JP7275405B2 (ja) 2023-05-17
AU2021227687B2 (en) 2023-02-23
SI3872091T1 (sl) 2023-12-29
JP2023505613A (ja) 2023-02-09

Similar Documents

Publication Publication Date Title
MA56074B1 (fr) Anticorps contre le sars-cov-2
MA57574A1 (fr) Utilisation d'un composé nucléoside dans le traitement des maladies infectieuses à coronavirus
Staples Jr et al. Hepatitis C in the HIV (human immunodeficiency virus) Atlanta VA (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival
RU2007119390A (ru) Соединения 4-метоксиметил-пирролидин-2-карбоновой кислоты и их производные - ингибиторы вируса гепатита с
TNSN03130A1 (fr) Inhibiteurs de protease du vih, compositions les contenant, leurs utilisations pharmaceutiques et matieres pour leur synthese
NO20054264L (no) Ikke-Nukleoside Revers Transkriptase-Inhibitorer I for behandling av HIV-medierte sydommer
WO2006044968A3 (fr) Polytherapie permettant de traiter des infections virales
Ruprecht et al. Interferon-α and 3′-azido-3′-deoxythymidine are highly synergistic in mice and prevent viremia after acute retrovirus exposure
PT98007A (pt) Processo para a preparacao de aminobenzodiazepinas e de composicoes farmaceuticas que as contem
AR034312A1 (es) Composicion de vacuna que comprende al menos un antigeno del virus de la inmunodeficiencia humana (vih), kit de vacunacion que la comprende, uso de un antigeno de vph y vhs para la preparacion de la composicion de vacuna y procedimiento para la preparacion de dicha vacuna
ATE92928T1 (de) Imidazo(2,1-b)benzothiazole und ihre saeureadditionssalze, verfahren und zwischenprodukte zu ihrer herstellung, ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zubereitungen.
GB1334327A (en) Compositions for and method of combating virus infections
CN113288892A (zh) 聚adp核糖聚合酶抑制剂在抗冠状病毒中的应用
US5519028A (en) Antiviral preparations
NO20051833L (no) 4-(3,5-dicyanofenoksy)pyrazolderivater for anvendelse som transkriptasemodulatorer ved behandling av IA HIV.
CN101287744A (zh) 抗病毒化合物
BÖTTIGER et al. Prevention of HIV-2 and SIV infections in cynomolgus macaques by prophylactic treatment with 3′-fluorothymidine
US20040006103A1 (en) Use of chloroquine, hydroxychloroquine and 4 amino-quinolinic derivatives to obtain a drug for the anti retroviral therapy, active towards HIV sensitive strains and towards HIV strains which are resistant to both nucleosidic and non-nucleosidic reverse transcriptase inhibitors and to proteases inhibitors
BE903675Q (fr) Compositions contenant des 1,2,4-triazole-3-carboxamides et leur methode d'utilisation
US5164376A (en) Method for treating retroviral infections with aryl-(2-pyrryl) keytone compound
US20050059745A1 (en) Antiviral therapy
KR900701278A (ko) 바이러스 감염 치료용 담즙산
McCullough et al. Human immunodeficiency virus infection: a review of the mode of infection, pathogenesis, disease course, and the general and clinical manifestations
Sepkowitz et al. Postexposure prophylaxis for human immunodeficiency virus: frequency of initiation and completion of newly recommended regimen
JPH03151324A (ja) 抗ウイルス剤